Activity of Ki11502 against a panel of kinases
| Kinase . | Ki11502, IC50 (nM) . | Imatinib, IC50 (nM) . |
|---|---|---|
| PDGFRα | <10 | <10 |
| PDGFRβ | <10 | <10 |
| PDGFRαT674II | 129.6 | >1000 |
| ABL | >1000 | 25 |
| KIT | 86.81 | 250 |
| KITT670I | 427.8 | >1000 |
| FLT3 | 37.54 | >1000 |
| FLT3D835Y | 541.6 | >1000 |
| KDR | 210 | >1000 |
| IGF1-R | >1000 | >1000 |
| EGFR | >1000 | >1000 |
| FGF-R2 | >1000 | >1000 |
| Kinase . | Ki11502, IC50 (nM) . | Imatinib, IC50 (nM) . |
|---|---|---|
| PDGFRα | <10 | <10 |
| PDGFRβ | <10 | <10 |
| PDGFRαT674II | 129.6 | >1000 |
| ABL | >1000 | 25 |
| KIT | 86.81 | 250 |
| KITT670I | 427.8 | >1000 |
| FLT3 | 37.54 | >1000 |
| FLT3D835Y | 541.6 | >1000 |
| KDR | 210 | >1000 |
| IGF1-R | >1000 | >1000 |
| EGFR | >1000 | >1000 |
| FGF-R2 | >1000 | >1000 |
PDGFR indicates platelet-derived growth factor receptor; FLT3, fms-related tyrosine kinae; IGF1-R, insulin-like growth factor 1 receptor; EGFR, epidermal growth factor receptor; and FGF-R2, fibroblast growth factor receptor.
Concentrations that cause 50% inhibition (IC50) are given.